Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Multiple-Ascending Doses of LY2979165 in Healthy Subjects.

Trial Profile

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Multiple-Ascending Doses of LY2979165 in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Feb 2017

At a glance

  • Drugs MP 101 Mediti Pharma (Primary)
  • Indications Bipolar disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 03 Feb 2017 Results of two phase 1 single and multiple dose studies (NCT01248052 and NCT01383967) published in the British Journal of Clinical Pharmacology
    • 13 Jun 2012 Actual patient number is 102 according to ClinicalTrials.gov.
    • 21 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top